Facebook Linkedin RSS Twitter Youtube
Home 2021

Levodopa

Regional Power: Japan’s Kyowa Kirin Builds on U.S. Growth
Cancer

Regional Power: Japan’s Kyowa Kirin Builds on U.S. Growth

Alex Philippidis -
0
FDA Extends PDUFA Date for Acorda’s Inbrija, 3 Days after Company Loses Ampyra Appeal
News

FDA Extends PDUFA Date for Acorda’s Inbrija, 3 Days after Company Loses Ampyra Appeal

GEN Staff Writer -
0
FDA Refuses to File Acorda NDA for Inbrija
Industry News

FDA Refuses to File Acorda NDA for Inbrija

GEN Staff Writer -
0
Adamas’ Gocovri Wins FDA Nod as First PD Treatment for Levodopa-Induced Dyskinesia
Drug Discovery

Adamas’ Gocovri Wins FDA Nod as First PD Treatment for Levodopa-Induced Dyskinesia

GEN Staff Writer -
0
Mitsubishi Tanabe to Buy Parkinson’s Disease Drugs Firm NeuroDerm for $1.1B
Drug Discovery

Mitsubishi Tanabe to Buy Parkinson’s Disease Drugs Firm NeuroDerm for $1.1B

GEN Staff Writer -
0
Lasker 2014 Awards Honor Five Scientists Excelling in Basic and Applied Clinical Research
News

Lasker 2014 Awards Honor Five Scientists Excelling in Basic and Applied Clinical Research

GEN Staff Writer -
0
MJFF Supports Trial Evaluating Treatment for Levodopa-Induced Dyskinesia
News

MJFF Supports Trial Evaluating Treatment for Levodopa-Induced Dyskinesia

GEN Staff Writer -
0
Envoy Awarded MJFF Grant to Develop Oral Drug for Parkinson Disease
Drug Discovery

Envoy Awarded MJFF Grant to Develop Oral Drug for Parkinson Disease

GEN Staff Writer -
0
Adolor Awarded $0.3M by MJFF to Develop PD Drugs for Levodopa-Induced Dyskinesia
News

Adolor Awarded $0.3M by MJFF to Develop PD Drugs for Levodopa-Induced Dyskinesia

GEN Staff Writer -
0
Pivotal Trial Shows Adding Safinamide to Levodopa Stabilizes Dyskinesia in PD for Two Years
News

Pivotal Trial Shows Adding Safinamide to Levodopa Stabilizes Dyskinesia in PD for Two Years

GEN Staff Writer -
0
12Page 1 of 2
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.